Table 1 Baseline characteristics of the study populations
Variables | T2DM (n = 89) | HCs (n = 100) | P value |
|---|---|---|---|
Sex | |||
Male, n (%) | 49 (55.1%) | 56 (56.0%) | 0.896 |
Female, n (%) | 40 (44.9%) | 44 (44.0%) | Â |
Ages (years) | 62 (53, 70) | 61 (54, 66) | 0.226 |
BMI (kg/m2) | 24.1 (22.1, 26.4) | 24.4 (22.3, 26.6) | 0.230 |
Days after full-course vaccination (days) | 50 (32, 88) | 57 (36, 75) | 0.534 |
Days between the 1st and 2nd doses | 27 (22, 33) | 26 (24, 33) | 0.646 |
COVID-19 vaccines | |||
CoronaVac, n (%) | 67 (75.3%) | 54 (54.0%) | 0.004 |
BBIBP-CorV, n (%) | 21 (23.6%) | 39 (39.0%) | Â |
BBIBP-CorV + CoronaVac, n (%) | 1 (1.1%) | 7 (7.0%) |  |
HbA1c (%) | 7.4 (6.4, 9.9) | – | – |
FPG (mmol/L) | 7.5 (6.3, 9.4) | 5.3 (5.0, 5.9) | 0.000 |
Laboratory examination | |||
Red blood cell count (1012/L) | 4.6 (4.2, 5.0) | 4.7 (4.4, 5.2) | 0.166 |
White blood cell count (109/L) | 6.0 (4.7, 7.2) | 5.9 (4.8, 6.9) | 0.691 |
Lymphocyte count (109/L) | 1.7 (1.3, 2.2) | 1.7 (1.5, 2.2) | 0.220 |
Platelet count (109/L) | 171 (174, 212) | 193 (166, 232) | 0.004 |